Clinical Trials Logo

Clinical Trial Summary

This is a proposed follow up study on the investigators previous gene transfer human clinical trial entitled "Administration of a Replication Deficient Adeno-associated Virus Gene Transfer Vector Expressing the Human CLN2 cDNA to the Brain of Children with Late Infantile Neuronal Ceroid Lipofuscinosis" (Weill Cornell IRB# 0401007010). As in the previous study, the investigators propose to administer a biologic by direct gene transfer into the brain and assess its safety on children with a fatal genetic disease of the central nervous system (CNS). The disease is Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL, a form of Batten disease). This will be accomplished by using delivery of a gene (method called gene transfer) to administer to the brain an experimental drug called AAVRh.10CUhCLN2, a gene transfer vector.


Clinical Trial Description

The investigators propose to assess a new drug to treat children with a form of Batten Disease called Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL). These children are born with genetic changes called mutations in their CLN2 gene that result in the inability of the brain to properly recycle proteins. The recycling failure leads to death of the nerve cells in the brain and progressive loss of brain function. Children with Batten disease are normal at birth but by age 2 to 4 have motor and vision problems which progress rapidly to death at age approximately 10 years old. There are no therapies available to treat the disease. The experimental gene transfer procedure treatment the investigators propose consists of augmenting the abnormal gene by a good copy. A virus is used to deliver the good gene to the nerve cells. Since the disease is due to an abnormal CLN2 gene, the aim of this study is to add a normal copy of the CLN2 gene to the brain of affected children to try to reverse death of cells in the brain. Previously the investigators have used a virus called adeno-associated virus 2 (AAV2) as the gene delivery system. That study showed that viral delivery of the gene was safe. We now propose to use a slightly different virus called AAVrh.10 as a gene delivery system and use 2 different doses of the virus. Children with Batten disease will get the drug injected into the brain and will receive extensive neurological assessment at intervals to determine if the transfer slows the rate of progress of the disease. The primary aims of the study are: (1) to assess the hypothesis that direct administration of AAVrh.10CUhCLN2 to the brain of children with LINCL can be achieved safely and with minimal toxicity; and (2) to evaluate the hypothesis that direct administration of AAVrh.10CUhCLN2 to the brain of children with LINCL will slow down or halt progression of the disease as assessed by neurological rating scales and quantitative MRI (primary variables). The investigators have recently completed a study in which the normal copy of the gene was surgically delivered to 12 locations in the brain in 10 children with LINCL. The children were assessed by a number of neurological and imaging parameters prior to and after gene transfer. The data demonstrated that the gene transfer was well tolerated and had a small impact on the progression of the disease and suggested that higher doses and a better delivery system may provide greater benefit. The previous study used the viral gene transfer vector adeno-associated virus type 2 (AAV2) at a dose of 2,000,000,000,000 molecules of the drug (2 x 10^12 particle units). The investigators now propose a very similar study with delivery of the identical payload with a slightly different viral gene delivery system based on the virus AAVrh.10. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01161576
Study type Interventional
Source Weill Medical College of Cornell University
Contact
Status Completed
Phase Phase 1
Start date August 19, 2010
Completion date December 31, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT02254863 - UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells Phase 1
Completed NCT01907087 - A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) Disease Phase 1/Phase 2
Recruiting NCT03307304 - Investigations of Juvenile Neuronal Ceroid Lipofuscinosis
Active, not recruiting NCT03770572 - Gene Therapy for Children With CLN3 Batten Disease Phase 1/Phase 2
Recruiting NCT06203106 - NYSCF Scientific Discovery Biobank
Completed NCT00151268 - Genotype - Phenotype Correlations of LINCL N/A
Recruiting NCT02435940 - Inherited Retinal Degenerative Disease Registry
Completed NCT01035424 - Genotype-Phenotype Correlations of Late Infantile Neuronal Ceroid Lipofuscinosis
Completed NCT00151216 - Safety Study of a Gene Transfer Vector for Children With Late Infantile Neuronal Ceroid Lipofuscinosis Phase 1
Active, not recruiting NCT04273243 - Long-Term Follow Up of CLN6 Batten Disease Subjects Following Gene Transfer
Recruiting NCT03285425 - Natural History of Neuronal Ceroid Lipofuscinosis, Batten's CLN6 Diseae
Completed NCT00176904 - Stem Cell Transplant for Inborn Errors of Metabolism Phase 2/Phase 3
Recruiting NCT03333200 - Longitudinal Study of Neurodegenerative Disorders
Completed NCT02678689 - A Safety, Tolerability, and Efficacy Study of Intracerebroventricular BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease Phase 2
Completed NCT02485899 - An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease Phase 1/Phase 2
Active, not recruiting NCT05174039 - An Open-label Safety, Pharmacokinetic, and Efficacy Study of Miglustat for the Treatment of CLN3 Disease Phase 1/Phase 2
Terminated NCT01698229 - Collection of Cerebrospinal Fluid in Healthy Children N/A
Enrolling by invitation NCT03862274 - Examining Developmental Outcomes of Children Diagnosed With CLN2 Disease
Recruiting NCT01873924 - Clinical and Neuropsychological Investigations in Batten Disease
Recruiting NCT04613089 - Natural History and Longitudinal Clinical Assessments in NCL / Batten Disease, the International DEM-CHILD Database